BridgeBio Oncology Therapeutics, Inc. 8-K

What Happened
BridgeBio Oncology Therapeutics announced that Eli Wallace, Ph.D. resigned as a member of the board and as a Class III director and was succeeded by Pedro J. Beltran, Ph.D. as President and Chief Executive Officer effective April 20, 2026. On April 27, 2026 the company entered a Consulting Agreement with Dr. Wallace, effective retroactively April 21, 2026, under which he will provide advisory services for up to 12 months. Under the agreement Dr. Wallace’s sole compensation is the continued vesting of his outstanding equity awards; certain vested stock options may be exercisable for up to the earlier of two years after his termination of service or the options’ original expiration date. The company also entered a Separation Agreement and Release providing Tier 1 severance benefits under its Executive Severance Plan.

Key Details

• Resignation/succession: Eli Wallace resigned; Pedro J. Beltran, Ph.D. became President & CEO and Class III director effective April 20, 2026.
• Consulting term: Consulting Agreement entered April 27, 2026, effective April 21, 2026, for a 12‑month term unless earlier terminated.
• Compensation & options: Dr. Wallace’s exclusive consulting compensation is continued vesting of outstanding equity awards; vested options may be exercisable until the earlier of (i) two years after termination of service or (ii) the original option expiration date.
• Severance: Per a Separation Agreement executed April 27, 2026 and the company’s Executive Severance Plan, Dr. Wallace is entitled to Tier 1 severance if terminated by the company other than for “cause.”

Why It Matters
This filing documents a leadership transition and an advisory arrangement that preserves access to the departing executive’s R&D knowledge while limiting cash payments (compensation is in the form of continued equity vesting). Investors should note potential impacts on the company’s stock-based compensation expense and any Tier 1 severance obligations, and that the full Consulting Agreement will be filed as an exhibit to BridgeBio Oncology Therapeutics’ upcoming Form 10-Q for the quarter ending June 30, 2026.